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Abstract. Patients on cyclosporin A (CsA) often
develop hyperuricaemia and gout. In transplant
patients the use of uricosuric drugs for treating hyperu-
ricaemia may be preferable to allopurinol because of
the known interaction of the latter with azathioprine.
We therefore prospectively studied the uricosuric effi-
cacy of 100 mg benzbromarone (Bbr;Desuric®) daily
in 25 CsA-treated renal transplant patients with stable
graft function and hyperuricaemia (> 359 umol/1 for
females, >491 umol/1 for males).
Benzbromarone decreased plasma uric acid from
579± 18 umol/1 to 313±24 umol/1 (mean + SEM; P<
0.001) and thereby normalized plasma uric acid in 21
of 25 patients. The remaining four patients had creatin-
ine clearances between 21 and 25 ml/min, the lowest
of the entire study group. Mean fractional clearance
of uric acid increased from 5.4 ±0.4% to 17.2 ±1.0%
(i><0.001). The relative decrease of plasma uric acid
closely correlated with baseline creatinine clearance
(r = 0.67; P<0.001). CsA trough values were not influ-
enced. None of the patients experienced any significant
side-effects. As an unexpected find-ing, urinary uric
acid excretion increased from 2082+ 175 umol/24 h to
3233 ±232 umol/24 h after 4 weeks' treatment with
benzbromarone.
In conclusion, benzbromarone normalized plasma
uric acid in all CsA-treated renal transplant recipients
with a creatinine clearance > 25 ml/min. Due to its
excellent efficacy and lack of significant side-effects,
benzbromarone appears to be preferable to allopurinol
in CsA-treated renal transplant recipients with a creati-
nine clearance over 25 ml/min.
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Introduction
Transplant patients on cyclosporin A (CsA) have a
greater prevalence of hyperuricaemia than patients on
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conventional immunosuppression [1]. Asymptomatic
hyperuricaemia occurs in up to 80% of patients, gout
in 5-24% of patients [2,3]. A substantial number of
patients therefore need treatment for hyperuricaemia.
Since hyperuricaemia in these patients is mainly due
to reduced renal uric acid clearance and not to
increased uric acid production [3], increasing uric acid
elimination via the kidney is a sensible approach.
Moreover the interaction of allopurinol with azathio-
prine, which can lead to life-threatening leukopenia,
militates against the use of allopurinol in patients on
combined immunosuppression with CsA and azathio-
prine. Since the efficacy of uricosuric drugs has never
been formally evaluated in CsA-treated renal trans-
plant patients, we undertook a prospective study to
answer the following questions: does the uricosuric
drug benzbromarone effectively lower plasma uric acid
in CsA-treated renal transplant patients? Is there a
lower limit of graft function for the uricosuric effect?
Does benzbromarone cause any significant drug inter-
action or side-effects in these patients?
Subjects and methods
Twenty-five consecutive CsA-treated renal transplant patients
(10 females, 15 males) with stable graft function and hyperur-
icaemia were studied prospectively after giving written
informed consent. Inclusion criteria were: (1) CsA therapy
with (n = 14) or without (n = 11) azathioprine and/or prednis-
one, (2) hyperuricaemia (>359|imol/l for females,
>491 |imol/l for males), (3) stable graft function. Exclusion
criteria were: (1) current treatment with any uricosuric drug
or allopurinol, (2) unstable graft function, (3) known poor
compliance. Two patients in the study group had a history
of gout. After baseline measurements, the patients received
100 mg of benzbromarone daily for 4 weeks in addition to
their established medication. No specific prescriptions regard-
ing minimal fluid intake or urine alkalinization were given.
Patients were asked for side-effects at 1 and 4 weeks of
treatment. The following laboratory tests were performed at
the beginning and at the end of the study: whole blood
chemistry profile; platelet, red and white blood cell count;
CsA blood trough levels; 24-h urine excretion of creatinine,
urea, uric acid, protein, and calcium; microscopic examina-
tion of urine sediment. In addition the same examinations
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except 24-h urine analysis were performed after 1 week of
treatment to detect early signs of toxicity or drug interaction.
Laboratory methods
Uric acid concentrations in plasma and urine were measured
using a uncase method (Hitachi 737, Boehringer Mannheim),
plasma and urine creatinine concentrations by a creatininase
assay (Wako Chemicals GmbH, Neuss; Hitachi 737,
Boehringer Mannheim). CsA whole blood 12 h trough values
were measured with a TDx-FPIA-method (Abbott TDx
cyclosporin monoclonal).
Statistical analysis
Statistical evaluation was performed using Student's paired
t test. Correlations were evaluated using linear least squares
regression; /><0.05 was considered significant and two-sided
tests were used throughout. Data are given as mean ± SEM.
Results
Plasma creatinine of the study patients ranged between
82 umol/1 and 276 umol/1, creatinine clearance between
21 and 78 ml/min. Graft function remained stable
throughout the study period (Table 1).
Benzbromarone significantly decreased mean plasma
uric acid from 579± 18 umol/1 to 313 ±24 umol/1
(P< 0.001; Table 1). Fall of plasma uric acid was rapid
and sustained in all but two patients (Figure 1), and
there was no significant change beyond the first week
for the group as a whole. For 21 of 25 patients this
decrease meant normalization of plasma uric acid.
Fractional uric acid clearance increased from
5.4±0.4% to 17.2 + 1.0% (/><0.001; Table 1). There
was a good correlation between the percent decrease
of plasma uric acid and both plasma creatinine (r =
-0.68; P< 0.001; Figure 2) and creatinine clearance
(r = 0.67; P<0.001; Figure 3). Similarly, the increase
of fractional uric acid clearance correlated well with
creatinine (r=-0.54; P< 0.005) and creatinine clear-
ance (r = 0.58; P<0.005). The four patients in whom
normalization of plasma uric acid was not achieved
had creatinine clearances between 21 and 25 ml/min,
the lowest of the whole study group.
While 24-h urinary creatinine excretion remained
unchanged (9885 ±2540 umol/24 h versus 9971 ±2377
Table 1. Results
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CCR (ml/min)
P-UA (umol/1)
fCUA (%)
UVUA (umol/24 h)
UVCreat (umol/24 h)
CsA trough level (ug/1)
Before Bbr
49 ±4
579±18
5.4 ±0.4
2082 ±175
9885 ±2541
162±80
1 week Bbr
281 ±20*"
4 weeks Bbr
47 ±4
313±24*«*
17.2±1.0*"
3233 ±232**
9971 ±2377
162 ±72
Data are given as mean±SEM; **P<0.01; ***/><0.001.
Creatinine clearance (CCR), plasma uric acid (P-UA), fractional
clearance of uric acid (fCUA), urinary excretion of uric acid
(UVUA), urinary excretion of creatinine (UVCreat).
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Fig. 1. Plasma uric (umol/1) acid before, during, and at the end of
benzbromarone (Bbr) treatment.
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Fig. 2. Relative decrease (in percent of initial values) of plasma uric
acid in function of plasma creatinine.
umol/24 h), urinary uric acid excretion was signific-
antly increased at the end of the 4 weeks treatment
(2082 +175 umol/24 h before Bbr, 3233 + 232
umol/24 h after 4 weeks of Bbr, P< 0.001). Only two
patients' uric acid excretion, however, was in the
hyperuricosuric (> 4800 umol/24 h) range, namely
4862 umol/24 h and 7105 umol/24 h. Microscopic
evaluation of urine sediment revealed no pathological
microhaematuria nor crystalluria during treatment.
There were no changes of CsA trough levels (162 ± 80
before versus 162 ± 72 ug/1 after Bbr) and no signs of
toxicity in the haematological or in the blood chemistry
profile. Except for one patient with known irritable
colon who reported increased diarrhoea, no side-effects
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Fig. 3. Relative decrease (in percent of initial values) of plasma uric
acid in function of creatinine clearance.
were noted. There were no episodes of gout or any
evidence of urolithiasis.
Discussion
The efficacy of uricosuric drugs, well-documented in
gouty, non-transplant patients [4], has not been form-
ally evaluated in CsA-treated renal transplant patients
so far. The use of uricosurics in these patients could
be questioned because (a) reduced GFR [5,6] and (b)
impaired tubular handling of uric acid due to CsA-
induced proximal tubular dysfunction [7-11] could
potentially impair their effect. The present data, how-
ever, demonstrate an excellent efficacy of benzbroma-
rone in lowering plasma uric acid within 1 week in all
patients with a creatinine clearance > 25 ml/min. Even
in the four patients with a creatinine clearance
< 25 ml/min there was still a moderate effect at 1 week
(fall of plasma uric acid 17-41%). The fact that this
effect was not sustained in two of these patients, may
be due to non-compliance. Similar results have been
reported in non-transplant patients with comparable
renal function [6,12,13] as well as in a group of renal
transplant patients on conventional immunosuppres-
sion [14]. There is therefore no evidence for impaired
uricosuric efficacy of benzbromarone in CsA-treated
renal transplant patients. That benzbromarone is less
effective in patients with low creatinine clearances most
probably reflects diminished postsecretory reabsorp-
tion in the renal tubule such as occurs with increasing
renal failure [15,16]. Postsectretory reabsorption is the
presumptive site of action of uricosuric drugs [17].
The 50% increase of urinary uric acid excretion
(Table 1) after 4 weeks of benzbromarone represents
an interesting, albeit unanticipated finding. Our
expectation was that despite the increment in clearance,
urinary excretion of uric acid would return to baseline
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by reaching a new steady state after 4 weeks' treatment
with benzbromarone. Two possible mechanisms may
be considered: either steady state conditions were not
yet achieved because some of the patients were still
mobilizing uric acid from soft tissue microdeposits, or
extrarenal (mainly intestinal) uric acid excretion might
have decreased with decreasing plasma uric acid [18,19]
and therefore a higher percentage of daily uric acid
load was excreted via the kidney. Still, true hyperurico-
suria (>4500 umol/24 h for females, >4800 umol/24 h
for men) occurred in only two patients. Microscopic
analysis of urine sediment never gave any evidence of
increased crystalluria or haematuria. Since intratubular
flow in the distal nephron of renal transplant patients
(having only one functioning kidney) is greater than
in normals, their risk of stone formation is probably
lower at any degree of uric acid excretion. Of course,
a larger and longer study would be required to ascertain
that this risk is indeed not increased. In our personal
experience, following 12 renal transplant patients for
at least 1.5 years (median 4 years, range 1.5-6 years),
we never observed any stone formation.
We conclude that benzbromarone is an efficacious
and safe drug for treating hyperuricaemia in CsA-
treated renal transplant patients with a creatinine clear-
ance over 25 ml/min. In patients with creatinine
clearances below 25 ml/min or plasma creatinine over
approximately 250 umol/1, allopurinol probably
remains the preferred drug. Either treatment, however,
should be given to symptomatic patients only.
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